Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-003 in moderate to severe persistent allergic asthma
NCT07342803Phase 2Recruiting
- Sponsor
- LongBio Pharma
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LP-003 in allergic asthma, sponsored by LongBio Pharma. Started Jan 2025; status: recruiting.
02
Drugs
LP-003
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT07342803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07342803.